Expec vaccine development
Ended Project Grant Awarded Last action
- Award ID
- R56AI177630
- Recipient
-
Baylor College Of Medicine UEI FXKMA43NTV21
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $376,764
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- The evolution of bacterial resistance to antibiotics is precipitating a medical crisis that will cause millions of deaths and cost trillions in dollars. A major bacterial driver of resistance is so-called extraintestinal pathogenic e. Coli (expec), a member of the human microbiome that has reached pandemic status because of its deadly combination of resistance and virulence. Expec is now the leading cause of resistance-related human mortality worldwide. There is no FDA-approved vaccine, and efforts to identify novel targets for vaccine development have been hampered by the pleiotropic nature of this bacterium's pangenome. Using an exhaustive comparative genomics approach of > 20,000 sequenced strains covering all sequence types, pathotypes, and phylogenies, we uncovered two high-priority virulence factor targets that met multiple vaccine- development criteria. Hypothesizing that immunological blockade of the function of these two factors will provide a one-two punch that prevents critical steps in systemic infection and invasive disease, we propose here pre-clinical studies aimed at testing the prophylactic efficacy of such an approach. This includes a comprehensive evaluation of the vaccine's performance to prevent three distinct types of expec infection, a thorough optimization of basic vaccine parameters, innovation around novel adjuvants, and finally, the immunological mechanism of protection. Successful completion of this project will yield knowledge as to whether targeting factors important for invasive infection is an effective strategy to reduce or eliminate global expec-induced mortality and morbidity.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$23,236 | |
| Original award | $400,000 |
Quick answers
Who received award R56AI177630?
R56AI177630 was awarded to Baylor College Of Medicine by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 15, 2024.
How much is award R56AI177630 worth?
$376,764 has been obligated on R56AI177630.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award